Intuitive Surgical Revises Bylaws to Align with SEC Universal Proxy Rules and Enhance Shareholder Meeting Governance

Implementation of SEC Universal Proxy Rule Compliance

Intuitive Surgical’s Board has revised the company’s bylaws to incorporate provisions consistent with the SEC’s universal proxy rules, which aim to standardize shareholder communications during director elections. The company will now disregard votes for nominees submitted by shareholders failing to meet universal proxy requirements. A key element mandates that shareholder proponents must solicit holders of at least 67% of outstanding shares before presenting director nominees at shareholder meetings. This threshold acts as a significant deterrent to activist campaigns and ensures nominations have broad investor support.

Embedding these provisions into the bylaws provides Intuitive Surgical with a clear and formal mechanism to enforce universal proxy compliance, eliminating the need for ad hoc legal decisions during shareholder meetings. This approach enhances transparency for shareholders and the governance team by establishing definitive criteria for valid nominations ahead of proxy contests.

Strengthened Disclosure Requirements for Shareholder Nominations and Proposals

The amended bylaws introduce more detailed disclosure requirements for shareholders nominating directors or submitting proposals. The company now requires clearer reporting of synthetic equity holdings using SEC-defined terms, improving transparency around derivative positions and economic interests. Shareholders must also disclose investment dates and intentions, enabling the board and investors to evaluate the timing and motives behind proposals. Additionally, the full text of any proposed bylaw amendments must be included in proxy statements, removing ambiguity about the matters on which shareholders vote.

These enhanced disclosures aim to increase transparency regarding the parties driving governance proposals and their financial interests. By clarifying investment intent and timing, shareholders can better assess whether proposals are long-term strategic initiatives or short-term tactics. Including complete bylaw amendment language in proxy materials ensures shareholders have full access to the proposed changes.

Procedural Limits on Director Nominations

The bylaws now explicitly prohibit shareholders from nominating more director candidates than the number of available seats at the shareholder meeting, preventing slate-packing tactics that can cause confusion or complicate voting. This ensures ballots remain focused on genuine governance choices.

Further, only record holders—not merely beneficial owners—can request nominee questionnaires, ensuring nominators have formal ownership stakes. Shareholders must also be physically present at the meeting to proceed with their nominees, reinforcing procedural integrity and preventing indirect manipulation of the nomination process.

Proxy Card Color and Solicitation Requirements

To reduce shareholder confusion in proxy contests, the bylaws require any shareholder soliciting proxies to use proxy cards of a color other than white. Since official company proxy materials traditionally use white cards, this color differentiation helps shareholders quickly identify the source of proxy materials and avoid voting errors.

This measure addresses longstanding governance concerns by visually distinguishing shareholder-initiated solicitations, thereby minimizing accidental votes and improving clarity during contested elections.

Special Meeting Request Procedures and Record Date Disclosures

The amended bylaws formalize procedures for shareholders requesting record dates to call special meetings. Such shareholders must provide disclosures similar to those required for director nominations or proposals, including details about holdings, investment intent, and beneficial ownership structures.

These standardized disclosures across governance actions ensure consistent transparency about who is initiating governance efforts, reducing selective disclosure and enhancing informed decision-making among shareholders and the board.

Updated Voting Standards for Non-Election Corporate Actions

The bylaws revise the voting standard for corporate actions other than director elections to require a majority of votes cast, excluding abstentions and broker non-votes. This method counts only votes actively cast for or against a measure, simplifying calculations and preventing abstentions or broker non-votes from diluting the influence of participating shareholders.

This votes-cast majority standard emphasizes the intent of engaged shareholders and may facilitate approval of management-backed proposals when many shares are held passively or abstain. The change does not appear to apply to director elections, which typically follow plurality or majority standards under Delaware law or company-specific bylaws.

Technical and Conforming Updates

Alongside substantive governance reforms, the amended bylaws include technical amendments to align with Delaware corporate law and SEC regulations. These adjustments cover procedural details, formatting, and administrative provisions, ensuring consistency without altering governance substance. The full Amended and Restated Bylaws are filed as Exhibit 3.1, providing transparency for investors and stakeholders.

Such technical updates are standard governance maintenance, helping the company’s bylaws remain current with evolving legal requirements.

Impact on Investors and Governance Trends

The extensive bylaw revisions mirror broader governance trends among large-cap public companies, particularly in capital-intensive sectors like surgical robotics and medical devices. By adopting universal proxy rules, enhancing disclosures, and clarifying nomination procedures, Intuitive Surgical aligns with expectations from major asset managers and institutional investors. These changes may raise barriers for activist shareholders seeking director contests or alternative proposals due to increased disclosure thresholds and procedural requirements.

Investors should note that these amendments introduce greater formality and transparency in shareholder engagement, potentially reducing surprise governance challenges. Reviewing the full amended bylaws is advisable to understand how these provisions may affect future director nominations or shareholder proposals.

Board’s Governance Framework Enhancement

The Board’s July 23, 2026, decision to amend and restate the bylaws underscores its commitment to regulatory compliance and governance strengthening. The filing does not indicate prior shareholder approval, consistent with Delaware law permitting boards to amend bylaws absent conflicting shareholder provisions.

The comprehensive nature of these amendments suggests a thorough governance review involving corporate governance teams, legal counsel, and possibly institutional investor input, reflecting best practices and regulatory expectations in the medical device and surgical robotics industries.